Related references
Note: Only part of the references are listed.Regulation of protein turnover by acetyltransferases and deacetylases
Karin Sadoul et al.
BIOCHIMIE (2008)
Targeting the apoptotic pathway with BCL-2 inhibitors sensitizes primary chronic lymphocytic leukemia cells to vesicular stomatitis virus-induced oncolysis
Vanessa Fonseca Tumilasci et al.
JOURNAL OF VIROLOGY (2008)
Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma
Paul Richardson et al.
LEUKEMIA & LYMPHOMA (2008)
Exponential enhancement of oncolytic vesicular stomatitis virus potency by vector-mediated suppression of inflammatory responses in vivo
Jennifer Altomonte et al.
MOLECULAR THERAPY (2008)
Phase I trial of MS-275, a histone deacetylase inhibitor, administered weekly in refractory solid tumors and lymphoid malignancies
Shivaani Kummar et al.
CLINICAL CANCER RESEARCH (2007)
Oncolytic viruses in cancer therapy
Markus J. V. Vaha-Koskela et al.
CANCER LETTERS (2007)
Targeted inflammation during oncolytic virus therapy severely compromises tumor blood flow
Caroline J. Breitbach et al.
MOLECULAR THERAPY (2007)
Bax-dependent mitochondrial membrane permeabilization enhances IRF3-mediated innate immune response during VSV infection
Ehssan Sharif-Askari et al.
VIROLOGY (2007)
Histone deacetylase inhibitors: molecular mechanisms of action
W. S. Xu et al.
ONCOGENE (2007)
The RAS/Raf1/MEK/ERK signaling pathway facilitates VSV-mediated oncolysis: Implication for the defective interferon response in cancer cells
Josh A. Noser et al.
MOLECULAR THERAPY (2007)
Phase IIB multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma
Elise A. Olsen et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Vorinostat for treatment of cutaneous manifestations of advanced primary cutaneous T-cell lymphoma
Bhupinder S. Mann et al.
CLINICAL CANCER RESEARCH (2007)
Engineering oncolytic measles virus to circumvent the intracellular innate immune response
Iana Haralambieva et al.
MOLECULAR THERAPY (2007)
Discovery and development of SAHA as an anticancer agent
P. A. Marks
ONCOGENE (2007)
Histone deacetylase inhibitors suppress IFNα-induced up-regulation of promyelocytic leukemia protein
Jana Vlasakova et al.
BLOOD (2007)
Dimethyl sulfoxide to vorinostat: Development of this histone deacetylase inhibitor as an anticancer drug
Paul A. Marks et al.
NATURE BIOTECHNOLOGY (2007)
Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma, (CTCL)
Madeleine Duvic et al.
BLOOD (2007)
Histone deacetylase inhibitors: Biology and mechanism of action
Janice M. Mehnert et al.
CANCER JOURNAL (2007)
Drug Insight: role of the androgen receptor in the development and progression of prostate cancer
Mary-Ellen Taplin
NATURE CLINICAL PRACTICE ONCOLOGY (2007)
Myxoma virus and oncolytic virotherapy: a new biologic weapon in the war against cancer
Marianne M. Stanford et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2007)
FDA approval summary: Vorinostat for treatment of advanced primary cutaneous T-cell lymphoma
Bhupinder S. Mann et al.
ONCOLOGIST (2007)
MS-275, a potent orally available inhibitor of histone deacetylases - The development of an anticancer agent
Holger Hess-Stumpp et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2007)
Interferons, immunity and cancer immunoediting
Gavin P. Dunn et al.
NATURE REVIEWS IMMUNOLOGY (2006)
Experimental therapy of malignant gliomas using the inhibitor of histone deacetylase MS-275
LY Eyüpoglu et al.
MOLECULAR CANCER THERAPEUTICS (2006)
Positive and negative regulation of the innate antiviral response and beta interferon gene expression by deacetylation
I Nusinzon et al.
MOLECULAR AND CELLULAR BIOLOGY (2006)
Negative regulation of the retinoic acid-inducible gene I-induced antiviral state by the ubiquitin-editing protein A20
RT Lin et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer
S Minucci et al.
NATURE REVIEWS CANCER (2006)
Recent progress in the battle between oncolytic viruses and tumours
KA Parato et al.
NATURE REVIEWS CANCER (2005)
Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma
QC Ryan et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Systemic therapy of experimental breast cancer metastases by mutant vesicular stomatitis virus in immune-competent mice
O Ebert et al.
CANCER GENE THERAPY (2005)
Drug Insight: histone deacetylase inhibitors - development of the new targeted anticancer agent suberoylanilide hydroxamic acid
WK Kelly et al.
NATURE CLINICAL PRACTICE ONCOLOGY (2005)
Expression profiling of sodium butyrate (NaB)-treated cells: identification of regulation of genes related to cytokine signaling and cancer metastasis by NaB
J Joseph et al.
ONCOGENE (2004)
Sensitivity of prostate tumors to wild type and M protein mutant vesicular stomatitis viruses
M Ahmed et al.
VIROLOGY (2004)
Induction of interferon-stimulated gene expression and antiviral responses require protein deacetylase activity
HM Chang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Activation of TBK1 and IKKε kinases by vesicular stomatitis virus infection and the role of viral ribonucleoprotein in the development of interferon antiviral immunity
BR tenOever et al.
JOURNAL OF VIROLOGY (2004)
Defective translational control facilitates vesicular stomatitis virus oncolysis
S Balachandran et al.
CANCER CELL (2004)
VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents
DF Stojdl et al.
CANCER CELL (2003)
Impairment of interferon-induced IRF-7 gene expression due to inhibition of ISGF3 formation by trichostatin A
P Génin et al.
JOURNAL OF VIROLOGY (2003)
Replication-selective virotherapy for cancer: Biological principles, risk management and future directions
D Kirn et al.
NATURE MEDICINE (2001)
Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus
DF Stojdl et al.
NATURE MEDICINE (2000)
Alpha/beta interferons potentiate virus-induced apoptosis through activation of the FADD/caspase-8 death signaling pathway
S Balachandran et al.
JOURNAL OF VIROLOGY (2000)
Share Paper
